x

This website uses cookies to improve your experience. Continue if you are OK with this or read more in our privacy policy. 




Myriad hit with gene testing suit

14-10-2013

Myriad hit with gene testing suit

US biotech company Myriad Genetics is facing claims that 14 of its patents covering tests for breast and ovarian cancer are invalid and non-infringed by Quest Diagnostics.


myriad genetics, quest diagnostics, brca1, brca2, aclu

WIPR

Payment types accepted